Cardiac myxoma is the most common benign tumor of the heart. It presents with a variety of clinical signs and symptomatology making diagnosis frequently quite a challenge. We review our experience with 41 patients who underwent surgical intervention for cardiac myxoma between 1994 and 2011. All patients' preoperative, intraoperative and postoperative characteristics were recorded. They all had a standard sternotomy and cardiopulmonary bypass with cardioplegic cardiac arrest and were followed up with clinical examination and echocardiography. The surgical goal was to remove not only the tumor but the whole area of attachment to prevent recurrence. Biatrial approach facilitated the complete excision of the tumor. Surgical excision of cardiac myxoma carries a low-operative risk and gives excellent short- and long-term results.
Methods This review is based on research of the current literature regarding the epidemiology of CM, its clinical presentation, diagnosis, and treatment. The PubMed database was searched for eligible studies and the search was restricted to the years 2000 to 2019. The search term was "cardiac myxoma" and we included observational or retrospective studies with large samples of patients who were treated for CM only. In addition, the data of interest to the present review were long-term follow-up, the recurrence rate during follow-up, and the survival rate after CM resection. Additionally, we looked for studies on novel surgical techniques for CM resection and those describing unusual CM location or clinical presentation. The primary source for data extraction were 24 articles from 15 countries, which reported on a total of 2205 patients with CM (TABLE 1). 1-24 We included studies from Europe, North and South America,
Ascending aorta and proximal aortic arch replacement with brief duration of deep hypothermic circulatory arrest combined with retrograde cerebral perfusion is a safe method with acceptable short- and long-tem results.
NT-proBNP levels are predictive of mortality following TAVI. There is a differential early evolution of their levels between the TF and TA patients and a significant decline later in both groups.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.